Pieris Pharmaceuticals Ownership
| PIRS Stock | USD 16.77 0.84 5.27% |
Shares in Circulation | First Issued 2016-06-30 | Previous Quarter 1000 K | Current Value 1000 K | Avarage Shares Outstanding 1000 K | Quarterly Volatility 0.0 |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pieris |
Pieris Stock Ownership Analysis
About 53.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.36. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pieris Pharmaceuticals recorded a loss per share of 12.11. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 23rd of April 2024. Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts. Pieris Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Pieris Pharmaceuticals contact Stephen JD at 857 246 8998 or learn more at https://www.pieris.com.Besides selling stocks to institutional investors, Pieris Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pieris Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pieris Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pieris Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Pieris Pharmaceuticals Insider Trades History
Less than 1% of Pieris Pharmaceuticals are currently held by insiders. Unlike Pieris Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pieris Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pieris Pharmaceuticals' insider trades
Pieris Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pieris Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pieris Pharmaceuticals backward and forwards among themselves. Pieris Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Pieris Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-06-30 | 334 | Group One Trading, Lp | 2024-06-30 | 323 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 164 | U.s. Bancorp | 2024-06-30 | 158 | Barclays Plc | 2024-06-30 | 63.0 | Wells Fargo & Co | 2024-06-30 | 60.0 | Jpmorgan Chase & Co | 2024-06-30 | 27.0 | Bank Of America Corp | 2024-06-30 | 13.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 7.0 | Bvf Inc | 2024-09-30 | 257.6 K | Adar1 Capital Management Llc | 2024-09-30 | 144.6 K |
Pieris Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pieris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pieris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pieris Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pieris Pharmaceuticals Outstanding Bonds
Pieris Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pieris Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pieris bonds can be classified according to their maturity, which is the date when Pieris Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pieris Pharmaceuticals Corporate Filings
F3 | 18th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 8th of November 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.